Cargando…

Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication

Immunodeficiency-associated vaccine-derived polioviruses (iVDPVs) have been isolated from primary immunodeficiency (PID) patients exposed to oral poliovirus vaccine (OPV). Patients may excrete poliovirus strains for months or years; the excreted viruses are frequently highly divergent from the paren...

Descripción completa

Detalles Bibliográficos
Autores principales: Aghamohammadi, Asghar, Abolhassani, Hassan, Kutukculer, Necil, Wassilak, Steve G., Pallansch, Mark A., Kluglein, Samantha, Quinn, Jessica, Sutter, Roland W., Wang, Xiaochuan, Sanal, Ozden, Latysheva, Tatiana, Ikinciogullari, Aydan, Bernatowska, Ewa, Tuzankina, Irina A., Costa-Carvalho, Beatriz T., Franco, Jose Luis, Somech, Raz, Karakoc-Aydiner, Elif, Singh, Surjit, Bezrodnik, Liliana, Espinosa-Rosales, Francisco J., Shcherbina, Anna, Lau, Yu-Lung, Nonoyama, Shigeaki, Modell, Fred, Modell, Vicki, Barbouche, Mohamed-Ridha, McKinlay, Mark A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5468416/
https://www.ncbi.nlm.nih.gov/pubmed/28952612
http://dx.doi.org/10.3389/fimmu.2017.00685
_version_ 1783243435938938880
author Aghamohammadi, Asghar
Abolhassani, Hassan
Kutukculer, Necil
Wassilak, Steve G.
Pallansch, Mark A.
Kluglein, Samantha
Quinn, Jessica
Sutter, Roland W.
Wang, Xiaochuan
Sanal, Ozden
Latysheva, Tatiana
Ikinciogullari, Aydan
Bernatowska, Ewa
Tuzankina, Irina A.
Costa-Carvalho, Beatriz T.
Franco, Jose Luis
Somech, Raz
Karakoc-Aydiner, Elif
Singh, Surjit
Bezrodnik, Liliana
Espinosa-Rosales, Francisco J.
Shcherbina, Anna
Lau, Yu-Lung
Nonoyama, Shigeaki
Modell, Fred
Modell, Vicki
Barbouche, Mohamed-Ridha
McKinlay, Mark A.
author_facet Aghamohammadi, Asghar
Abolhassani, Hassan
Kutukculer, Necil
Wassilak, Steve G.
Pallansch, Mark A.
Kluglein, Samantha
Quinn, Jessica
Sutter, Roland W.
Wang, Xiaochuan
Sanal, Ozden
Latysheva, Tatiana
Ikinciogullari, Aydan
Bernatowska, Ewa
Tuzankina, Irina A.
Costa-Carvalho, Beatriz T.
Franco, Jose Luis
Somech, Raz
Karakoc-Aydiner, Elif
Singh, Surjit
Bezrodnik, Liliana
Espinosa-Rosales, Francisco J.
Shcherbina, Anna
Lau, Yu-Lung
Nonoyama, Shigeaki
Modell, Fred
Modell, Vicki
Barbouche, Mohamed-Ridha
McKinlay, Mark A.
author_sort Aghamohammadi, Asghar
collection PubMed
description Immunodeficiency-associated vaccine-derived polioviruses (iVDPVs) have been isolated from primary immunodeficiency (PID) patients exposed to oral poliovirus vaccine (OPV). Patients may excrete poliovirus strains for months or years; the excreted viruses are frequently highly divergent from the parental OPV and have been shown to be as neurovirulent as wild virus. Thus, these patients represent a potential reservoir for transmission of neurovirulent polioviruses in the post-eradication era. In support of WHO recommendations to better estimate the prevalence of poliovirus excreters among PIDs and characterize genetic evolution of these strains, 635 patients including 570 with primary antibody deficiencies and 65 combined immunodeficiencies were studied from 13 OPV-using countries. Two stool samples were collected over 4 days, tested for enterovirus, and the poliovirus positive samples were sequenced. Thirteen patients (2%) excreted polioviruses, most for less than 2 months following identification of infection. Five (0.8%) were classified as iVDPVs (only in combined immunodeficiencies and mostly poliovirus serotype 2). Non-polio enteroviruses were detected in 30 patients (4.7%). Patients with combined immunodeficiencies had increased risk of delayed poliovirus clearance compared to primary antibody deficiencies. Usually, iVDPV was detected in subjects with combined immunodeficiencies in a short period of time after OPV exposure, most for less than 6 months. Surveillance for poliovirus excretion among PID patients should be reinforced until polio eradication is certified and the use of OPV is stopped. Survival rates among PID patients are improving in lower and middle income countries, and iVDPV excreters are identified more frequently. Antivirals or enhanced immunotherapies presently in development represent the only potential means to manage the treatment of prolonged excreters and the risk they present to the polio endgame.
format Online
Article
Text
id pubmed-5468416
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-54684162017-06-28 Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication Aghamohammadi, Asghar Abolhassani, Hassan Kutukculer, Necil Wassilak, Steve G. Pallansch, Mark A. Kluglein, Samantha Quinn, Jessica Sutter, Roland W. Wang, Xiaochuan Sanal, Ozden Latysheva, Tatiana Ikinciogullari, Aydan Bernatowska, Ewa Tuzankina, Irina A. Costa-Carvalho, Beatriz T. Franco, Jose Luis Somech, Raz Karakoc-Aydiner, Elif Singh, Surjit Bezrodnik, Liliana Espinosa-Rosales, Francisco J. Shcherbina, Anna Lau, Yu-Lung Nonoyama, Shigeaki Modell, Fred Modell, Vicki Barbouche, Mohamed-Ridha McKinlay, Mark A. Front Immunol Immunology Immunodeficiency-associated vaccine-derived polioviruses (iVDPVs) have been isolated from primary immunodeficiency (PID) patients exposed to oral poliovirus vaccine (OPV). Patients may excrete poliovirus strains for months or years; the excreted viruses are frequently highly divergent from the parental OPV and have been shown to be as neurovirulent as wild virus. Thus, these patients represent a potential reservoir for transmission of neurovirulent polioviruses in the post-eradication era. In support of WHO recommendations to better estimate the prevalence of poliovirus excreters among PIDs and characterize genetic evolution of these strains, 635 patients including 570 with primary antibody deficiencies and 65 combined immunodeficiencies were studied from 13 OPV-using countries. Two stool samples were collected over 4 days, tested for enterovirus, and the poliovirus positive samples were sequenced. Thirteen patients (2%) excreted polioviruses, most for less than 2 months following identification of infection. Five (0.8%) were classified as iVDPVs (only in combined immunodeficiencies and mostly poliovirus serotype 2). Non-polio enteroviruses were detected in 30 patients (4.7%). Patients with combined immunodeficiencies had increased risk of delayed poliovirus clearance compared to primary antibody deficiencies. Usually, iVDPV was detected in subjects with combined immunodeficiencies in a short period of time after OPV exposure, most for less than 6 months. Surveillance for poliovirus excretion among PID patients should be reinforced until polio eradication is certified and the use of OPV is stopped. Survival rates among PID patients are improving in lower and middle income countries, and iVDPV excreters are identified more frequently. Antivirals or enhanced immunotherapies presently in development represent the only potential means to manage the treatment of prolonged excreters and the risk they present to the polio endgame. Frontiers Media S.A. 2017-06-13 /pmc/articles/PMC5468416/ /pubmed/28952612 http://dx.doi.org/10.3389/fimmu.2017.00685 Text en Copyright © 2017 Aghamohammadi, Abolhassani, Kutukculer, Wassilak, Pallansch, Kluglein, Quinn, Sutter, Wang, Sanal, Latysheva, Ikinciogullari, Bernatowska, Tuzankina, Costa-Carvalho, Franco, Somech, Karakoc-Aydiner, Singh, Bezrodnik, Espinosa-Rosales, Shcherbina, Lau, Nonoyama, Modell, Modell, Barbouche and McKinlay. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Aghamohammadi, Asghar
Abolhassani, Hassan
Kutukculer, Necil
Wassilak, Steve G.
Pallansch, Mark A.
Kluglein, Samantha
Quinn, Jessica
Sutter, Roland W.
Wang, Xiaochuan
Sanal, Ozden
Latysheva, Tatiana
Ikinciogullari, Aydan
Bernatowska, Ewa
Tuzankina, Irina A.
Costa-Carvalho, Beatriz T.
Franco, Jose Luis
Somech, Raz
Karakoc-Aydiner, Elif
Singh, Surjit
Bezrodnik, Liliana
Espinosa-Rosales, Francisco J.
Shcherbina, Anna
Lau, Yu-Lung
Nonoyama, Shigeaki
Modell, Fred
Modell, Vicki
Barbouche, Mohamed-Ridha
McKinlay, Mark A.
Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication
title Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication
title_full Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication
title_fullStr Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication
title_full_unstemmed Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication
title_short Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication
title_sort patients with primary immunodeficiencies are a reservoir of poliovirus and a risk to polio eradication
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5468416/
https://www.ncbi.nlm.nih.gov/pubmed/28952612
http://dx.doi.org/10.3389/fimmu.2017.00685
work_keys_str_mv AT aghamohammadiasghar patientswithprimaryimmunodeficienciesareareservoirofpoliovirusandarisktopolioeradication
AT abolhassanihassan patientswithprimaryimmunodeficienciesareareservoirofpoliovirusandarisktopolioeradication
AT kutukculernecil patientswithprimaryimmunodeficienciesareareservoirofpoliovirusandarisktopolioeradication
AT wassilaksteveg patientswithprimaryimmunodeficienciesareareservoirofpoliovirusandarisktopolioeradication
AT pallanschmarka patientswithprimaryimmunodeficienciesareareservoirofpoliovirusandarisktopolioeradication
AT klugleinsamantha patientswithprimaryimmunodeficienciesareareservoirofpoliovirusandarisktopolioeradication
AT quinnjessica patientswithprimaryimmunodeficienciesareareservoirofpoliovirusandarisktopolioeradication
AT sutterrolandw patientswithprimaryimmunodeficienciesareareservoirofpoliovirusandarisktopolioeradication
AT wangxiaochuan patientswithprimaryimmunodeficienciesareareservoirofpoliovirusandarisktopolioeradication
AT sanalozden patientswithprimaryimmunodeficienciesareareservoirofpoliovirusandarisktopolioeradication
AT latyshevatatiana patientswithprimaryimmunodeficienciesareareservoirofpoliovirusandarisktopolioeradication
AT ikinciogullariaydan patientswithprimaryimmunodeficienciesareareservoirofpoliovirusandarisktopolioeradication
AT bernatowskaewa patientswithprimaryimmunodeficienciesareareservoirofpoliovirusandarisktopolioeradication
AT tuzankinairinaa patientswithprimaryimmunodeficienciesareareservoirofpoliovirusandarisktopolioeradication
AT costacarvalhobeatrizt patientswithprimaryimmunodeficienciesareareservoirofpoliovirusandarisktopolioeradication
AT francojoseluis patientswithprimaryimmunodeficienciesareareservoirofpoliovirusandarisktopolioeradication
AT somechraz patientswithprimaryimmunodeficienciesareareservoirofpoliovirusandarisktopolioeradication
AT karakocaydinerelif patientswithprimaryimmunodeficienciesareareservoirofpoliovirusandarisktopolioeradication
AT singhsurjit patientswithprimaryimmunodeficienciesareareservoirofpoliovirusandarisktopolioeradication
AT bezrodnikliliana patientswithprimaryimmunodeficienciesareareservoirofpoliovirusandarisktopolioeradication
AT espinosarosalesfranciscoj patientswithprimaryimmunodeficienciesareareservoirofpoliovirusandarisktopolioeradication
AT shcherbinaanna patientswithprimaryimmunodeficienciesareareservoirofpoliovirusandarisktopolioeradication
AT lauyulung patientswithprimaryimmunodeficienciesareareservoirofpoliovirusandarisktopolioeradication
AT nonoyamashigeaki patientswithprimaryimmunodeficienciesareareservoirofpoliovirusandarisktopolioeradication
AT modellfred patientswithprimaryimmunodeficienciesareareservoirofpoliovirusandarisktopolioeradication
AT modellvicki patientswithprimaryimmunodeficienciesareareservoirofpoliovirusandarisktopolioeradication
AT patientswithprimaryimmunodeficienciesareareservoirofpoliovirusandarisktopolioeradication
AT barbouchemohamedridha patientswithprimaryimmunodeficienciesareareservoirofpoliovirusandarisktopolioeradication
AT mckinlaymarka patientswithprimaryimmunodeficienciesareareservoirofpoliovirusandarisktopolioeradication